Pages that link to "Q44669178"
Jump to navigation
Jump to search
The following pages link to Phase II trial of gefitinib in recurrent glioblastoma (Q44669178):
Displaying 50 items.
- Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model (Q21133610) (← links)
- Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors (Q24676928) (← links)
- Recurrent Glioblastoma: Where we stand (Q26765042) (← links)
- Nonsurgical treatment of recurrent glioblastoma (Q26795560) (← links)
- Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date (Q26822717) (← links)
- G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues (Q26825769) (← links)
- Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods (Q26853516) (← links)
- EGFR Amplification and Glioblastoma Stem-Like Cells (Q26853549) (← links)
- Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges (Q26862516) (← links)
- Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk (Q26865911) (← links)
- Recent advancements in multimodality treatment of gliomas (Q27001724) (← links)
- Contemporary murine models in preclinical astrocytoma drug development (Q27026937) (← links)
- Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy (Q27320588) (← links)
- Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development (Q28475285) (← links)
- Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases (Q28829017) (← links)
- Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. (Q30361219) (← links)
- Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers (Q30412090) (← links)
- EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance (Q30456087) (← links)
- Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma (Q30541574) (← links)
- Present and potential future issues in glioblastoma treatment (Q31043603) (← links)
- Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol (Q33243912) (← links)
- PLXDC1 (TEM7) is identified in a genome-wide expression screen of glioblastoma endothelium (Q33259937) (← links)
- DNA-encoded antibody libraries: a unified platform for multiplexed cell sorting and detection of genes and proteins (Q33270725) (← links)
- Neurotrophin receptors expression and JNK pathway activation in human astrocytomas. (Q33304406) (← links)
- Predictive and prognostic markers in neuro-oncology (Q33311133) (← links)
- Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma (Q33346827) (← links)
- Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors (Q33364999) (← links)
- Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma (Q33369411) (← links)
- Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme (Q33387317) (← links)
- Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells (Q33406013) (← links)
- Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. (Q33407127) (← links)
- Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN. (Q33576476) (← links)
- Oncogene interactions are required for glioma development and progression as revealed by a tissue specific transgenic mouse model (Q33579323) (← links)
- Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies (Q33644407) (← links)
- Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence (Q33664297) (← links)
- Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma (Q33710967) (← links)
- Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma (Q33747609) (← links)
- A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses. (Q33777423) (← links)
- Recurrent high-grade glioma: a diagnostic and therapeutic challenge (Q33864058) (← links)
- Molecular targeting of glioblastoma: Drug discovery and therapies (Q33911283) (← links)
- Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux (Q34028148) (← links)
- Experimental approaches for the treatment of malignant gliomas (Q34127138) (← links)
- A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy (Q34132643) (← links)
- Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies (Q34132781) (← links)
- Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial (Q34132872) (← links)
- The origins of cancer robustness and evolvability. (Q34143477) (← links)
- Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma (Q34206363) (← links)
- Medical therapy of gliomas (Q34218761) (← links)
- EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy (Q34296575) (← links)
- Gliomagenesis and the use of neural stem cells in brain tumor treatment (Q34310698) (← links)